Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder

NCT00406315 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT00406315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00406315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2006
Completion date
March 31, 2009
Enrollment
255 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia